title: No relationship between the type of pituitary suppression for IVF and chromosomal abnormality rates of blastomeres: an observational study.
abstract: OBJECTIVE
  To investigate whether the incidence of chromosomally abnormal blastomeres is related to the type of pituitary suppression used in ovarian stimulation.
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  Tertiary referral center.
  
  
  METHODS
  The study involved 694 consecutive cycles; 320 belonged to agonist group and 374 to antagonist group, of patients' ≤ 37 years of age who underwent preimplantation genetic screening between October 1, 1992 until December 31, 2006. All of them (and their partners) had normal karyotyping results. Only the data of patients who had at least one embryo biopsy were analyzed.
  
  
  METHODS
  Preimplantation genetic screening (PGS).
  
  
  METHODS
  The primary outcome measure was detection of abnormal blastomeres on the total number of embryos analyzed.
  
  
  RESULTS
  The total abnormal ratio was statistically similar between the embryos of the two study groups (49.9 ± 28.1 vs. 50.2 ± 26.6). Likewise, a multivariate (linear regression) analysis indicated that the total abnormality ratio was not influenced by the type of stimulation when simultaneously adjusting for age, rank of trials, indication for preimplantation genetic screening, total gonadotropin amount, number of cumulus-oocyte complexes, and number of two pronuclear oocytes embryos. No difference was observed in ongoing pregnancy rates between agonists and antagonists (26.6% vs. 23.3%, respectively).
  
  
  CONCLUSIONS
  Based on our findings there is no difference in the proportion of abnormal blastomeres either when using gonadotropin-releasing hormone (GnRH) agonist, or antagonist protocol.
authors.affiliation: Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
authors.forename: Dimitra
authors.initials: D
authors.lastname: Kyrou
authors.forename: Willem
authors.initials: W
authors.lastname: Verpoest
authors.forename: Catherine
authors.initials: C
authors.lastname: Staessen
authors.forename: Anick
authors.initials: A
authors.lastname: De Vos
authors.forename: Patrick
authors.initials: P
authors.lastname: Haentjens
authors.forename: Inge
authors.initials: I
authors.lastname: Liebaers
authors.forename: Paul
authors.initials: P
authors.lastname: Devroey
mesh_terms: D000328:Adult; D001757:Blastomeres / Q000378:metabolism / Q000473:pathology*; D002869:Chromosome Aberrations / Q000706:statistics & numerical data*; D025063:Chromosome Disorders / Q000196:embryology / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D015536:Down-Regulation / Q000187:drug effects; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005307:Fertilization in Vitro / Q000009:adverse effects / Q000706:statistics & numerical data; D006801:Humans; D010062:Ovulation Induction / Q000379:methods* / Q000706:statistics & numerical data; D010902:Pituitary Gland / Q000187:drug effects* / Q000502:physiology; D010907:Pituitary Hormones / Q000037:antagonists & inhibitors; D011247:Pregnancy; D019836:Preimplantation Diagnosis / Q000706:statistics & numerical data; D012189:Retrospective Studies
chemical_list: D005300:Fertility Agents, Female; D010907:Pituitary Hormones